Literature DB >> 16821802

Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.

Jason Z Vlahakis1, Robert T Kinobe, Raymond J Bowers, James F Brien, Kanji Nakatsu, Walter A Szarek.   

Abstract

Several imidazole-dioxolane compounds were synthesized and evaluated as novel inhibitors of heme oxygenase (HO). These compounds, which include (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4-methyl-1,3-dioxolane (1) hydrochloride, are structurally distinct from metalloporphyrin HO inhibitors and lack the aminothiophenol moiety of azalanstat. They were found to be highly selective for the HO-1 isozyme (stress induced) and had substantially less inhibitory potency toward HO-2, the constitutive isozyme. These imidazole-dioxolane compounds are the first of their type known to exhibit this isozyme-selective HO inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16821802     DOI: 10.1021/jm0511435

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  In vivo inhibition of renal heme oxygenase with an imidazole-dioxolane inhibitor.

Authors:  Eva Csongradi; Trinity Vera; John M Rimoldi; Rama S V Gadepalli; David E Stec
Journal:  Pharmacol Res       Date:  2010-03-23       Impact factor: 7.658

Review 2.  HO-1 overexpression and underexpression: Clinical implications.

Authors:  George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham
Journal:  Arch Biochem Biophys       Date:  2019-08-16       Impact factor: 4.013

3.  Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds.

Authors:  Mona N Rahman; Dragic Vukomanovic; Jason Z Vlahakis; Walter A Szarek; Kanji Nakatsu; Zongchao Jia
Journal:  J R Soc Interface       Date:  2012-11-08       Impact factor: 4.118

Review 4.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 5.  Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  Transl Res       Date:  2015-06-23       Impact factor: 7.012

6.  Extracellular haem utilization by the opportunistic pathogen Pseudomonas aeruginosa and its role in virulence and pathogenesis.

Authors:  Susana Mouriño; Angela Wilks
Journal:  Adv Microb Physiol       Date:  2021-08-13       Impact factor: 3.517

Review 7.  Metalloporphyrins in the management of neonatal hyperbilirubinemia.

Authors:  David K Stevenson; Ronald J Wong
Journal:  Semin Fetal Neonatal Med       Date:  2009-12-16       Impact factor: 3.926

8.  Small molecule antivirulents targeting the iron-regulated heme oxygenase (HemO) of P. aeruginosa.

Authors:  Kellie Hom; Geoffrey A Heinzl; Suntara Eakanunkul; Pedro E M Lopes; Fengtian Xue; Alexander D MacKerell; Angela Wilks
Journal:  J Med Chem       Date:  2013-03-01       Impact factor: 7.446

9.  Renal Inhibition of Heme Oxygenase-1 Increases Blood Pressure in Angiotensin II-Dependent Hypertension.

Authors:  Eva Csongradi; Megan V Storm; David E Stec
Journal:  Int J Hypertens       Date:  2011-11-16       Impact factor: 2.420

10.  A novel, "double-clamp" binding mode for human heme oxygenase-1 inhibition.

Authors:  Mona N Rahman; Jason Z Vlahakis; Dragic Vukomanovic; Wallace Lee; Walter A Szarek; Kanji Nakatsu; Zongchao Jia
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.